Replies to post #112340 on Biotech Values

[10nisman]

Teva: we expect FDA decision on generic lovenox by end of January. We think our application is approvable but we can't guarantee that. Regardless if we get approved at end january or a bit later, we will be one of 3 or 4 players in the generic lovenox business.

Where did you hear/read this last statement? Bill Marth made no comments regarding Lovenox that I heard on the JPM webcast.

10nis

[DFRAI]

JBOG
Are you quoting someone? Are you having a "moment"? are you sleep walking?...eh

[pollyvonwog]

Once again, a stark contrast from TEVA's previous position.

[mcbio]

Regardless if we get approved at end january or a bit later, we will be one of 3 or 4 players in the generic lovenox business.

And if they don't get approved at the end of January or a bit later, then MNTA will likely continue to have the only approved generic Lovenox. Nothing too revealing here.

[alertmeipp]

it's not that complicated - they will keep saying approvable in near term in order to hurt MNTA's position. Get used to it.

[dewophile]

Teva: "it was a wonderful year for the US generics with the launch of venlafaxine [effexor] that really gave us a push in profits and profitability. we're not going to see that kind of launch in 2011 but instead of that we're going to have a long list of much smaller products

lovenox should represent - even as a 3rd or 4th generic - a 400-500M product annually. this can't be that far off from what generic effexor brought in during the 6 months exclusivity in 2010, and would still have to represent one of the largest sellers among their US generics. to say flat out they won't have a new launch of a large selling product in the US generics business in 2010 but rather lots of much smaller product launches tells me they are not confident they will get approval for lovenox early this year